SAB Biotherapeutics (SABS) Receivables - Other (2020 - 2021)
SAB Biotherapeutics (SABS) reported Receivables - Other of $6250.0 for Q4 2021, little changed on a YoY basis from $6250.0 in Q4 2020, and little changed quarter-over-quarter from $6250.0 in Q4 2020.
SAB Biotherapeutics (SABS) Receivables - Other (2020 - 2021) Analysis & Trends
SAB Biotherapeutics has reported Receivables - Other for 2 years, with the latest figure at $6250.0 in Q4 2021.
- For the quarter ending Q4 2021, Receivables - Other changed 0.0% year-over-year to $6250.0; the trailing twelve-month figure through Dec 2021 stood at $6250.0 (changed 0.0% YoY), and the FY2021 full-year result was $6250.0, changed 0.0% from the prior year.
- Receivables - Other for Q4 2021 stood at $6250.0, roughly flat from $6250.0 in the prior quarter.
- The five-year high for Receivables - Other was $6250.0 in Q4 2020, with the low at $6250.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 6,250.00 |
| Dec 31, 2021 | 6,250.00 |
| Dec 31, 2020 | 6,250.00 |
| Dec 31, 2020 | 6,250.00 |